Hypereosinophilic syndrome and mepolizumab.
Verzegnassi
Federico
F
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D018450:Disease Progression; D004359:Drug Therapy, Combination; D004804:Eosinophils / Q000187:drug effects; D005938:Glucocorticoids / Q000008:administration & dosage*; D006801:Humans; D017681:Hypereosinophilic Syndrome / Q000188:drug therapy*; D007958:Leukocyte Count; D011241:Prednisone / Q000008:administration & dosage*; D017211:Treatment Failure
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D005938:Glucocorticoids; C434107:mepolizumab; D011241:Prednisone